Calamos Advisors’s ANI Pharmaceuticals ANIP Stock Holding History

Calamos Advisors’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-18,673	Closed	-$1.36M	–	772
2019 Q3	$1.36M	Buy	+18,673	New	+$1.4M	0.01%	635

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ICOM

Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Calamos Advisors's ANIP Position: Q4 2019 in Review

Calamos Advisors sold out of ANI Pharmaceuticals (ANIP) in Q4 2019, closing a stake of 18,673 shares — an estimated $1.36M sold.

Calamos Advisors first reported a position in ANIP in Q3 2019 and held it in 1 quarter. The position peaked at $1.36M in Q3 2019. 170 funds tracked by Wall St. Rank hold ANIP as of Q4 2019.

Calamos Advisors reported no remaining ANI Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Calamos Advisors sold 18,673 ANI Pharmaceuticals shares in Q4 2019, an estimated $1.36M.
Calamos Advisors first reported a position in ANI Pharmaceuticals in Q3 2019 and held it in 1 quarter.
Calamos Advisors's ANI Pharmaceuticals position peaked at $1.36M in Q3 2019.
170 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2019.

Based on Calamos Advisors's 13F filing for Q4 2019, filed 15 Jan 2020.